Royce & Associates LP reduced its holdings in shares of Zynex, Inc. (NASDAQ:ZYXI – Free Report) by 10.1% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 71,181 shares of the company’s stock after selling 8,029 shares during the quarter. Royce & Associates LP owned approximately 0.19% of Zynex worth $854,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in ZYXI. JPMorgan Chase & Co. boosted its holdings in Zynex by 183.5% during the second quarter. JPMorgan Chase & Co. now owns 626,319 shares of the company’s stock worth $4,998,000 after purchasing an additional 405,396 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Zynex by 12.7% during the 1st quarter. BlackRock Inc. now owns 3,419,912 shares of the company’s stock worth $21,307,000 after buying an additional 384,548 shares during the last quarter. Federated Hermes Inc. grew its holdings in shares of Zynex by 1,148.0% in the 1st quarter. Federated Hermes Inc. now owns 222,563 shares of the company’s stock valued at $1,387,000 after acquiring an additional 204,729 shares in the last quarter. Congress Asset Management Co. MA acquired a new stake in shares of Zynex in the first quarter valued at about $1,382,000. Finally, Renaissance Technologies LLC increased its position in shares of Zynex by 147.0% in the first quarter. Renaissance Technologies LLC now owns 192,035 shares of the company’s stock valued at $1,196,000 after acquiring an additional 114,277 shares during the last quarter. 28.64% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of research analysts have weighed in on the company. TheStreet downgraded Zynex from a “b-” rating to a “c” rating in a research note on Friday, April 28th. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Zynex in a research note on Wednesday, April 12th.
Zynex Stock Performance
Zynex (NASDAQ:ZYXI – Get Free Report) last posted its earnings results on Thursday, July 27th. The company reported $0.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.05. The company had revenue of $44.95 million during the quarter, compared to the consensus estimate of $44.50 million. Zynex had a return on equity of 26.71% and a net margin of 9.72%. Research analysts expect that Zynex, Inc. will post 0.41 EPS for the current year.
About Zynex
Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device.
See Also
- Five stocks we like better than Zynex
- The How and Why of Investing in Large-Cap Stocks
- MarketBeat Week in Review – 07/31 – 08/04
- What is the Nikkei 225 index?
- 3 Best Meme ETFs to Buy Now
- How to Invest in Toy Stocks
- XPO Keeps Reaching New Highs: Markets Love the Stock
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.
